Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Андрогенная алопеция

Список литературы

  1. Heilmann-Heimbach S, Hochfeld LM, Paus R, Nöthen MM. Hunting the genes in male-pattern alopecia: how important are they, how close are we and what will they tell us? Exp Dermatol. 2016;25(4):251-7
  2. Nyholt DR, Gillespie NA, Heath AC, Martin NG. Genetic basis of male pattern baldness. J Invest Dermatol.2003;121(6):1561-4
  3. Rexbye H, Petersen I, Iachina M, Mortensen J, McGue M, Vaupel JW, et al. Hair loss among elderly men: etiology and impact on perceived age. J Gerontol A Biol Sci Med Sci. 2005;60(8):1077-82
  4. Birch MP, Messenger AG. Genetic factors predispose to balding and non- balding in men. European Journal of Dermatology. 2001;11:309-14
  5. Smith MA, Wells RS. Male-type alopecia, alopecia areata, and normal hair in women. Archives of Dermatology. 1964;89:155-8
  6. Redler S, Brockschmidt FF, Tazi-Ahnini R, Drichel D, Birch MP, Dobson K, et al. Investigation of the male pattern baldness major genetic susceptibility loci AR/EDA2R and 20p11 in female pattern hair loss. Br J Dermatol. 2012;166(6):1314- 8
  7. ip L, Zaloumis S, Irwin D, Severi G, Hopper J, Giles G, et al. Association analysis of oestrogen receptor beta gene (ESR2) polymorphisms with female pattern hair loss. Br J Dermatol. 2012;166(5):1131-4
  8. Redler S, Birch P, Drichel D, Hofmann P, Dobson K, Böhmer AC, et al. The oestrogen receptor 2 (ESR2) gene in female-pattern hair loss: replication of association with rs10137185 in German patients. Br J Dermatol. 2014;170(4):982-5
  9. Vexiau P, Chaspoux C, Boudou P, Fiet J, Abramovici Y, Rueda MJ, et al. Role of androgens in female-pattern androgenetic alopecia, either alone or associated with other symptoms of hyperandrogenism. Arch Dermatol Res. 2000;292(12):598-604
  10. Cela E, Robertson C, Rush K, Kousta E, White DM, Wilson H, et al. Prevalence of polycystic ovaries in women with androgenic alopecia. Eur J Endocrinol. 2003;149(5):439-42
  11. Kaliyadan F, Nambiar A, Vijayaraghavan S. Androgenetic alopecia: an update. Indian J Dermatol Venereol Leprol. 2013 Sep-Oct;79(5):613-25. doi: 10.4103/0378-6323.116730. PMID: 23974579.
  12. Wang TL, Zhou C, Shen YW, Wang XY, Ding XL, Tian S, et al. Prevalence of androgenetic alopecia in China: A community-based study in six cities. Br J Dermatol 2010;162:843-7
  13. Norwood OT. Incidence of female androgenetic alopecia (female pattern alopecia). Dermatol Surg 2001;27:53-4
  14. Birch MP, Messenger JF, Messenger AG. Hair density, hair diameter and the prevalence of female pattern hair loss. Br J Dermatol 2001; 144:297–304
  15. Piraccini BM, Alessandrini A. Androgenetic alopecia. G Ital Dermatol Venereol. 2014 Feb;149(1):15-24
  16. Gan DC, Sinclair RD. Prevalence of male and female pattern hair loss in Maryborough. J Invest Dermatol Symp Proc 2005;10:184-9
  17. Приказ Росстата от 18.12.2020 № 812 «Об утверждении форм федерального статистического наблюдения с указанием по их заполнению для организации Министерством здравоохранения Российской Федерации федерального статистического наблюдения в сфере охраны здоровья»
  18. Moravvej H, Pourani MR, Baghani M, Abdollahimajd F. Androgenetic alopecia and COVID-19: A review of the hypothetical role of androgens. Dermatol Ther. 2021 Jul;34(4):e15004. doi: 10.1111/dth.15004
  19. Wambier CG, Vaño-Galván S, McCoy J, Gomez-Zubiaur A, Herrera S, Hermosa-Gelbard Á, Moreno-Arrones OM, Jiménez-Gómez N, González-Cantero A, Fonda-Pascual P, Segurado- Miravalles G, Shapiro J, Pérez-García B, Goren A. Androgenetic alopecia present in the majority of patients hospitalized with COVID-19: The "Gabrin sign". J Am Acad Dermatol. 2020 Aug;83(2):680-682. doi: 10.1016/j.jaad.2020.05.079
  20. Müller Ramos P, Ianhez M, Amante Miot H. Alopecia and grey hair are associated with COVID-19 Severity. Exp Dermatol. 2020 Dec;29(12):1250-1252. doi: 10.1111/exd.14220
  21. Moradi F, Enjezab B, Ghadiri-Anari A. The role of androgens in COVID-19. Diabetes Metab Syndr. 2020 Nov-Dec;14(6):2003-2006. doi: 10.1016/j.dsx.2020.10.014
  22. Мельниченко О.О., Сакания Л.Р., Пирузян А.Л., Корсунская И.М. Андрогенная алопеция и коронавирусная инфекция. Consilium Medicum. 2021; 23 (8): 617–620. doi: 10.26442/20751753.2021.8.201086
  23. Ludwig E. Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex. Br J Dermatol 1977;97(3):247-54
  24. Olsen E.A. 1999. The midline part: an important physical clue to the clinical diagnosis of androgenetic alopecia in women. J Am Acad Dermatol; 40:106-10
  25. Blume-Peytavi U, Blumeyer A, Tosti A, Finner A, Marmol V, Trakatelli M, et al. S1 guideline for diagnostic evaluation in androgenetic alopecia in men, women and adolescents. Br J Dermatol. 2011;164(1):5-15
  26. Olsen EA. Androgenetic alopecia. In: Olsen EA, editor. Disorders of Hair Growth: Diagnosis and Treatment. New York: McGraw-Hill; 1994. p. 257-83
  27. Alessandrini A, Starace M, D'Ovidio R, Villa L, Rossi A, Stan TR, Calzavara-Pinton P, Piraccini BM. Androgenetic alopecia in women and men: Italian guidelines adapted from European Dermatology Forum/European Academy of Dermatology and Venereology guidelines. G Ital Dermatol Venereol. 2020 Oct;155(5):622-631
  28. van Zuuren EJ, Fedorowicz Z, Schoones J. Interventions for female pattern hair loss. Cochrane Database Syst Rev. 2016 May 26;2016(5):CD007628
  29. Olsen EA. Female pattern hair loss. J Am Acad Dermatol 2001; 45 (Suppl. 3):S70–80.
  30. Sinclair R, Wewerinke M, Jolley D. Treatment of female pattern hair loss with oral antiandrogens. British Journal of Dermatology 2005;152(3):466‐73
  31. Sinclair R, Jolley D, Mallari R, Magee J. The reliability of horizontally sectioned scalp biopsies in the diagnosis of chronic diffuse telogen hair loss in women. Journal of the American Academy of Dermatology 2004;51(2):189‐99
  32. Hamilton JB. Patterned loss of hair in man; types and incidence. Ann N Y Acad Sci 1951; 53:708– 28
  33. Norwood OT. Male pattern baldness: classification and incidence. South Med J 1975; 68:1359–65
  34. Neven ACH, Laven J, Teede HJ, Boyle JA. A Summary on Polycystic Ovary Syndrome: Diagnostic Criteria, Prevalence, Clinical Manifestations, and Management According to the Latest International Guidelines. Semin Reprod Med. 2018;36(1):5-12
  35. Carmina E, Guastella E, Longo RA. Advances in the Diagnosis and Treatment of PCOS. Curr Pharm Des. 2016;22(36):5508-5514
  36. McDonald KA, Shelley AJ, Colantonio S, Beecker J. Hair pull test: Evidence-based update and revision of guidelines. J Am Acad Dermatol. 2017 Mar;76(3):472-477. doi: 10.1016/j.jaad.2016.10.002. Epub 2016 Dec 20. PMID: 28010890
  37. Goodman NF, Cobin RH, Futterweit W, Glueck JS, Legro RS, Carmina E; American Association of Clinical Endocrinologists (AACE); American College of Endocrinology (ACE); Androgen Excess and PCOS Society. American Association of Clinical Endocrinologists, American College Of Endocrinology, And Androgen Excess and Pcos Society Disease State Clinical Review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome - part 2. Endocr Pract. 2015 Dec;21(12):1415-26
  38. Keen MA, Shah IH, Sheikh G. Cutaneous Manifestations of Polycystic Ovary Syndrome: A Cross- Sectional Clinical Study. Indian Dermatol Online J. 2017;8(2):104-110
  39. Rodgers R, Avery J, Moore V, Davies M, Azziz R, Stener-Victorin E, Moran L, Robertson S, Stepto N, Norman R, Teede HJ. Complex diseases and co-morbidities: polycystic ovary syndrome and type 2 diabetes mellitus. Endocr Connect. 2019 Feb 1. pii: EC-18-0502.R2
  40. D'Amico AV, Roehrborn CG. Effect of 1 mg/day finasteride on concentrations of serum prostate- specific antigen in men with androgenic alopecia: a randomised controlled trial. Lancet Oncol. 2007 Jan;8(1):21-5
  41. Carmina E, Azziz R, Bergfeld W, Escobar-Morreale HF, Futterweit W, Huddleston H, Lobo R, Olsen E. Female pattern hair loss and androgen excess: a report from the multidisciplinary androgen excess and PCOS committee. J Clin Endocrinol Metab. 2019 Jul 1;104(7):2875-2891. doi: 10.1210/jc.2018-02548. PMID: 30785992
  42. Gibson-Helm M, Teede H, Dunaif A, Dokras A, et al. Delayed diagnosis and a lack of information associated with dissatisfaction in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2017;102(2): 604–12
  43. Dokras A, Saini S, Gibson-Helm M, Schulkin J, Cooney L, Teede H. Gaps in knowledge among physicians regarding diagnostic criteria and management of polycystic ovary syndrome. Fertil Steril 2017;107(6): 1380–6.e1
  44. Balen AH, Morley LC, Misso M, Franks S, Legro RS, Wijeyaratne CN, et al. The management of anovulatory infertility in women with polycystic ovary syndrome: An analysis of the evidence to support the development of global WHO guidance. Hum Reprod Update 2016;22(6):687–708
  45. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and -cell function from fasting plasma glucose and insulin concentration in man. Diabetologia. 1985;28:412-419
  46. Andersen M, Glintborg D. Diagnosis and follow-up of type 2 diabetes in women with PCOS: a role for OGTT? Eur J Endocrinol. 2018 Sep;179(3):D1-D14. doi: 10.1530/EJE-18-0237
  47. Anagnostis P, Tarlatzis BC, Kauffman RP. Polycystic ovarian syndrome (PCOS): Long-term metabolic consequences. Metabolism. 2018;86:33-43
  48. Nolan CJ, Prentki M. Insulin resistance and insulin hypersecretion in the metabolic syndrome and type 2 diabetes: Time for a conceptual framework shift. Diab Vasc Dis Res. 2019 Mar;16(2):118- 127
  49. Sorokina Yu.A., Zanozina O.V., Postnikova A.D. The insulin resistance indices: necessity and opportunities in type 2 diabetes mellitus management. Klinicheskayameditsina. 2020;98(7):529- 535. DOI: http://dx.doi.org/10.30629/0023-2149-2020-98-7-529-535
  50. Starace M, Orlando G, Alessandrini A, Piraccini BM. Female Androgenetic Alopecia: An Update on Diagnosis and Management. Am J Clin Dermatol. 2020 Feb;21(1):69-84. doi: 10.1007/s40257- 019-00479-x. PMID: 31677111
  51. Inui S, Nakajima T, Itami S. Scalp dermoscopy of androgenetic alopecia in Asian people. J Dermatol. 2009 Feb;36(2):82-5. doi: 10.1111/j.1346-8138.2009.00593.x. PMID: 19284450
  52. Lacarrubba F, Dall'Oglio F, Rita Nasca M, Micali G. Videodermatoscopy enhances diagnostic capability in some forms of hair loss. Am J Clin Dermatol. 2004;5(3):205-8. doi: 10.2165/00128071-200405030-00009. PMID: 15186200
  53. Rakowska A, Slowinska M, Kowalska-Oledzka E, Olszewska M, Rudnicka L. Dermoscopy in female androgenic alopecia: method standardization and diagnostic criteria. Int J Trichology. 2009 Jul;1(2):123-30. doi: 10.4103/0974-7753.58555. PMID: 20927234; PMCID: PMC2938574
  54. Ross EK, Vincenzi C, Tosti A. Videodermoscopy in the evaluation of hair and scalp disorders. J Am Acad Dermatol. 2006 Nov;55(5):799-806. doi: 10.1016/j.jaad.2006.04.058. Epub 2006 Jul 28. PMID: 17052485
  55. de Lacharrière O, Deloche C, Misciali C, Piraccini BM, Vincenzi C, Bastien P, Tardy I, Bernard BA, Tosti A. Hair diameter diversity: a clinical sign reflecting the follicle miniaturization. Arch Dermatol. 2001 May;137(5):641-6. PMID: 11346342
  56. Атлас трихоскопии. Дерматоскопия заболеваний волос и кожи головы/пер. с англ. Под ред. Ю.Овчаренко. – Харьков: Издат.дом «Харизма плюс», 2019. – 507 с
  57. Deloche C, de Lacharrière O, Misciali C, Piraccini BM, Vincenzi C, Bastien P, Tardy I, Bernard BA, Tosti A. Histological features of peripilar signs associated with androgenetic alopecia. Arch Dermatol Res. 2004 Mar;295(10):422-8. doi: 10.1007/s00403-003-0447-y. Epub 2004 Jan 31. PMID: 14758487
  58. Wallace MP, de Berker DA. Hair diagnoses and signs: the use of dermatoscopy. Clin Exp Dermatol. 2010 Jan;35(1):41-6. doi: 10.1111/j.1365-2230.2009.03383.x. Epub 2009 Jun 22. PMID: 19549236
  59. Van Neste D. Female patients complaining about hair loss: documentation of defective scalp hair dynamics with contrast-enhanced phototrichogram. Skin Res Technol. 2006 May;12(2):83-8. doi: 10.1111/j.0909-752X.2006.00202.x. PMID: 16626380
  60. Gassmueller J, Rowold E, Frase T, Hughes-Formella B. Validation of TrichoScan technology as a fully-automated tool for evaluation of hair growth parameters. Eur J Dermatol. 2009 May- Jun;19(3):224-31. doi: 10.1684/ejd.2009.0640. Epub 2009 Feb 17. PMID: 19220982
  61. R. Hoffmann, H. Lüdtke, M. Hoffman-Wecker, B. J. Hughes-Formella. Digital imaging for measuring of hair growth on the human scalp In: E. Berardesca et al. (eds); Non Invasive Diagnostic Techniques in Clinical Dermatology (2014), Page 413-422
  62. Van Neste D, Trüeb RM. Critical study of hair growth analysis with computer-assisted methods. J Eur Acad Dermatol Venereol. 2006 May;20(5):578-83. doi: 10.1111/j.1468-3083.2006.01568.x. PMID: 16684287
  63. Kanti V, Hillmann K, Kottner J, Stroux A, Canfield D, Blume-Peytavi U. Effect of minoxidil topical foam on frontotemporal and vertex androgenetic alopecia in men: a 104-week open-label clinical trial. J Eur Acad Dermatol Venereol. 2016 Jul;30(7):1183-9. doi: 10.1111/jdv.13324. Epub 2015 Sep 21. PMID: 26387973
  64. Гаджигороева А.Г., Потекаев Н.Н. , Цимбаленко Т.В., Жукова О.В. Результаты многоцентрового открытого рандомизированного сравнительного исследования по изучению преимущества, эффективности и переносимости лечения выпадения волос у женщин с использованием моно- и комбинированной терапии препаратами для роста волос. Клиническая дерматология и венерология. 2020;19(4): 570-576
  65. Hillmann K, Garcia Bartels N, Kottner J, Stroux A, Canfield D, Blume-Peytavi U. A Single-Centre, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Investigate the Efficacy and Safety of Minoxidil Topical Foam in Frontotemporal and Vertex Androgenetic Alopecia in Men. Skin Pharmacol Physiol. 2015;28(5):236-44. doi: 10.1159/000375320. Epub 2015 Mar 3. PMID: 25765348
  66. Blume-Peytavi U, Kunte C, Krisp A, Garcia Bartels N, Ellwanger U, Hoffmann R. Comparison of the efficacy and safety of topical minoxidil and topical alfatradiol in the treatment of androgenetic alopecia in women. J Dtsch Dermatol Ges. 2007 May;5(5):391-5. English, German. doi: 10.1111/j.1610-0387.2007.06295.x. PMID: 17451383
  67. Canfield D. Photographic documentation of hair growth in androgenetic alopecia. Dermatol Clin 1996; 14:713–21
  68. Sinclair R, Jolley D, Mallari R et al. Morphological approach to hair disorders. J Investig Dermatol Symp Proc 2003; 8:56–64
  69. Vujovic A, Del Marmol V. The female pattern hair loss: review of etiopathogenesis and diagnosis. Biomed Res Int. 2014;2014:767628. doi: 10.1155/2014/767628. Epub 2014 Apr 9. PMID: 24812631; PMCID: PMC4000932
  70. Whiting DA. Diagnostic and predictive value of horizontal sections of scalp biopsy specimens in male pattern androgenetic alopecia. J Am Acad Dermatol. 1993 May;28(5 Pt 1):755-63. doi: 10.1016/0190-9622(93)70106-4. Erratum in: J Am Acad Dermatol 1993 Oct;29(4):554. PMID: 8496421
  71. Goren A, Castano JA, McCoy J, Bermudez F, Lotti T. Novel enzymatic assay predicts minoxidil response in the treatment of androgenetic alopecia. Dermatol Ther. 2014 May-Jun;27(3):171-3. doi: 10.1111/dth.12111. Epub 2013 Nov 27. PMID: 24283387
  72. McCoy J, Goren A, Kovacevic M, Shapiro J. Minoxidil dose response study in female pattern hair loss patients determined to be non-responders to 5% topical minoxidil. J Biol Regul Homeost Agents. 2016;30(4):1153–1155
  73. V.Kanti, A. Messenger, G. Dobos, P. Reygagne, A. Finner, A. Blumeyer, M. Trakatelli, A. Tosti, V. del Marmol, B.M. Piraccini, A. Nast, U. Blume-Peytavi. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men – short version. JEADV 2018, 32, 11–22
  74. V. Kanti, K. Hillmann, J. Kottner, A. Stroux, D. Canfield, U. Blume-Peytavi Effect of minoxidil topical foam on frontotemporal and vertex androgenetic alopecia in men: a 104- week open-label clinical trial. JEADV 2015, р.1-7
  75. Pazoki-Toroudi H, Babakoohi S, Nilforoushzadeh MA et al. Therapeutic effects of minoxidil high extra combination therapy in patients with androgenetic alopecia. SKINmed 2012; 10: 276– 282
  76. DeVillez RL, Jacobs JP, Szpunar CA et al. Androgenetic alopecia in the female. Treatment with 2% topical minoxidil solution. Arch Dermatol 1994; 130: 303– 307
  77. Lucky AW, Piacquadio DJ, Ditre CM et al. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol 2004; 50: 541– 553
  78. Kanti V, Messenger A, Dobos G, Reygagne P, Finner A, Blumeyer A, Trakatelli M, Tosti A, Del Marmol V, Piraccini BM, Nast A, Blume-Peytavi U. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men - short version. J Eur Acad Dermatol Venereol. 2018 Jan;32(1):11-22. doi: 10.1111/jdv.14624. Epub 2017 Nov 27. PMID: 29178529
  79. Adil A, Godwin M. The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis. J Am Acad Dermatol. 2017 Jul;77(1):136-141.e5. doi: 10.1016/j.jaad.2017.02.054. Epub 2017 Apr 7. PMID: 28396101
  80. Kaufman KD, Olsen EA, Whiting D, Savin R, DeVillez R, Bergfeld W, et al. Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group. Journal of the American Academy of Dermatology. 1998;39(4 Pt 1):578-89
  81. Price VH, Menefee E, Sanchez M, Ruane P, Kaufman KD. Changes in hair weight and hair count in men with androgenetic alopecia after treatment with finasteride, 1 mg, daily. Journal of the American Academy of Dermatology. 2002;46(4):517-23
  82. Price VH, Menefee E, Sanchez M, Kaufman KD. Changes in hair weight in men with androgenetic alopecia after treatment with finasteride (1 mg daily): three- and 4-year results. Journal of the American Academy of Dermatology. 2006;55(1):71- 4
  83. Whiting DA, Olsen EA, Savin R, Halper L, Rodgers A, Wang L, et al. Efficacy and tolerability of finasteride 1 mg in men aged 41 to 60 years with male pattern hair loss. European journal of dermatology EJD. 2003;13(2):150-60
  84. Sato A, Takeda A. Evaluation of efficacy and safety of finasteride 1 mg in 3177 Japanese men with androgenetic alopecia. Journal of Dermatology. 2012;39(1):27- 32
  85. Rossi A, Cantisani C, Scarno M, Trucchia A, Fortuna MC, Calvieri S. Finasteride, 1 mg daily administration on male androgenetic alopecia in different age groups: 10-year follow-up. Dermatologic Therapy. 2011;24(4):455-61
  86. Olsen EA, Hordinsky M, Whiting D, Stough D, Hobbs S, Ellis ML, et al. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. Journal of the American Academy of Dermatology. 2006;55(6):1014-23
  87. Stough D. Dutasteride improves male pattern hair loss in a randomized study in identical twins. Journal of cosmetic dermatology. 2007;6(1):9-13
  88. Jung JY, Yeon JH, Choi JW, Kwon SH, Kim BJ, Youn SW, et al. Effect of dutasteride 0.5 mg/d in men with androgenetic alopecia recalcitrant to finasteride. International Journal of Dermatology. 2014;53(11):1351-7
  89. Eun HC, Kwon OS, Yeon JH, Shin HS, Kim BY, Ro BI, et al. Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: A randomized, double- blind, placebo-controlled, phase III study. Journal of the American Academy of Dermatology. 2010;63(2):252-8
  90. Gupta A. K., Charrette A. The efficacy and safety of 5α-reductase inhibitors in androgenetic alopecia: a network meta-analysis and benefit–risk assess- ment of finasteride and dutasteride. J Dermatolog Treat 2014; 25 (2): 156-161
  91. Boersma IH, Oranje AP, Grimalt R, Iorizzo M, Piraccini BM, Verdonschot EH. The effectiveness of finasteride and dutasteride used for 3 years in women with androgenetic alopecia . Indian J Dermatol Venereol Leprol 2014;80:521-5
  92. Yeon JH, Jung JY, Choi JW, Kim BJ, Youn SW, Park KC, et al. 5 mg/day finasteride treatment for normoandrogenic Asian women with female pattern hair loss. Journal of the European Academy of Dermatology and Venereology. 2011;25(2):211-4
  93. Oliveira-Soares R, E Silva JM, Correia MP, Andre MC. Finasteride 5 mg/day Treatment of Patterned Hair Loss in Normo-androgenetic Postmenopausal Women. International Journal of Trichology. 2013;5(1):22-5
  94. Azarchi S, Bienenfeld A, Lo Sicco K, Marchbein S, Shapiro J, Nagler AR. Androgens in women: Hormone-modulating therapies for skin disease. J Am Acad Dermatol. 2019 Jun;80(6):1509-1521. doi: 10.1016/j.jaad.2018.08.061. Epub 2018 Oct 10. PMID: 30312645
  95. Trüeb RM, Swiss Trichology Study Group. Finasteride treatment of patterned hair loss in normoandrogenic postmenopausal women. Dermatology 2004;209:202-7
  96. Camacho F. Hirsutismo: enfoque dclinico terapeutico. Act Terap Dermatol; 24:190-206, 2001
  97. Iorizzo M, Vincenzi C, Voudouris S, Piraccini BM, Tosti A. Finasteride treatment of female pattern hair loss. Arch Dermatol 2006;142:298-302
  98. Olszewska M, Rudnicka L. Effective treatment of female androgenic alopecia with dutasteride. J Drugs Dermatol 2005;4:637-40
  99. Lobo R.A., Shoupe D., Serafini P., et al. The effects of two doses of spironolactone on serum androgens and anagen hair in hirsute women. Fertil Steril, 1985; 43(2): 200–5
  100. Hoedemaker C, van Egmond S, Sinclair R: Treatment of female pattern hair loss with a combination ofspironolactone and minoxidil. Australas J Dermatol 2007; 48: 43–45
  101. Paradisi R, Porcu E, Fabbri R, Seracchioli R, Battaglia C, Venturoli S. Prospective cohort study on the effects and tolerability of flutamide in patients with female pattern hair loss. Ann Pharmacother. 2011 Apr;45(4):469-75. doi: 10.1345/aph.1P600. Epub 2011 Apr 12. PMID: 21487083
  102. Carmina E, Lobo RA. Treatment of hyperandrogenic alopecia in women. Fertil Steril. 2003 Jan;79(1):91-5. doi: 10.1016/s0015-0282(02)04551-x. PMID: 12524069
  103. Hajheydari Z., Akbari J., Saeedi M., Shokoohi L. Comparing the therapeuticeffects of finasteride gel and tablet in treatment of the androgenetic alopecia. Indian J Dermatol Venereol Leprol. – 2009; 47–51
  104. McElwee Ph.D., Jerry Shapiro. Promising Therapies for Treating and/or Preventing Androgenic Alopecia // Skin Therapy Letter. 2012; 17
  105. Teede H, Tassone EC, Piltonen T, Malhotra J, Mol BW, Peña A, Witchel SF, Joham A, McAllister V, Romualdi D, Thondan M, Costello M, Misso ML. Effect of the combined oral contraceptive pill and/or metformin in the management of polycystic ovary syndrome: A systematic review with meta-analyses. Clin Endocrinol (Oxf). 2019 Oct;91(4):479-489
  106. Wang QY, et al. Comparison of drospirenone-with cyproterone acetate-containing oral contraceptives, combined with metformin and lifestyle modifications in women with polycystic ovary syndrome and metabolic disorders: A prospective randomized control trial. Chinese medical journal. 2016; 129(8):883-90
  107. Feng W, et al. Management of polycystic ovarian syndrome with Diane-35 or Diane-35 plus metformin. Gynecological Endocrinology. 2016; 32(2):147-50
  108. Shah A, Dodson WC, Kris-Etherton PM, et al. Effects of Oral Contraception and Lifestyle Modification on Incretins and TGF-ß Superfamily Hormones in PCOS. J Clin Endocrinol Metab. 2021 Jan 1;106(1):108-119
  109. Amiri M, Nahidi F, Yarandi RB, Khalili D, Tohidi M, Tehrani FR. Effects of oral contraceptives on the quality of life of women with polycystic ovary syndrome: a crossover randomized controlled trial. Health Qual Life Outcomes. 2020 Aug 31;18(1):293
  110. Fonseka S, Wijeyaratne CN, Gawarammana IB, Kalupahana NS, Rosairo S, Ratnatunga N, Kumarasiri R. Effectiveness of Low-dose Ethinylestradiol/Cyproterone Acetate and Ethinylestradiol/Desogestrel with and without Metformin on Hirsutism in Polycystic Ovary Syndrome: A Randomized, Double-blind, Triple-dummy Study. J Clin Aesthet Dermatol. 2020 Jul;13(7):18-23
  111. Gadalla MA, Norman RJ, Tay CT, Hiam DS, Melder A, Pundir J, Thangaratinam S, Teede HJ, Mol BWJ, Moran LJ. Medical and Surgical Treatment of Reproductive Outcomes in Polycystic Ovary Syndrome: An Overview of Systematic Reviews. Int J Fertil Steril. 2020 Jan;13(4):257-270. doi: 10.22074/ijfs.2020.5608
  112. Aversa A, La Vignera S, Rago R,Gambineri A, Nappi RE, Calogero AE and Ferlin A (2020) Fundamental Concepts and Novel Aspects of Polycystic Ovarian Syndrome: Expert Consensus Resolutions.Front. Endocrinol. 11:516.Doi: 10.3389/fendo.2020.00516
  113. Escobar-Morreale HF Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol. 2018 May;14(5):270-284
  114. Rogers NE, Avram MR: Medical treatments for male and female pattern hair loss. J Am Acad Dermatol 2008; 59: 547–566
  115. Trüeb R. M. Understanding Pattern Hair Loss—Hair Biology Impacted by Genes, Androgens, Prostaglandins and Epigenetic Factors //Indian Journal of Plastic Surgery. – 2021
  116. York K. et al. A review of the treatment of male pattern hair loss //Expert opinion on pharmacotherapy. – 2020. – Т. 21. – №. 5. – С. 603-612
  117. Bertoli M. J. et al. Female pattern hair loss: A comprehensive review //Dermatologic therapy. – 2020. – Т. 33. – №. 6. – С. e14055
  118. Teede, H. J., Misso, M. L., Costello, M. F., Dokras, A., Laven, J., … Moran, L. (2018). Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Clinical Endocrinology, 89(3), 251–268. doi:10.1111/cen.13795
  119. Доброхотова Ю.Э., Лапина И.А., Чирвон Т.Г., Таранов В.В. Новые возможности интегративной терапии пациенток с синдромом поликистозных яичников и нарушениями углеводного и липидного обмена. Результаты сравнительного исследования. РМЖ. Мать и дитя. 2020;3(3):169–173
  120. Egger A, Resnik SR, Aickara D, Maranda E, Kaiser M, Wikramanayake TC, Jimenez JJ. Examining the Safety and Efficacy of Low-Level Laser Therapy for Male and Female Pattern Hair Loss: A Review of the Literature. Skin Appendage Disord. 2020 Sep;6(5):259-267. doi: 10.1159/000509001. Epub 2020 Jul 7. PMID: 33088809; PMCID: PMC7548873
  121. Leavitt M, Charles G, Heyman E, Michaels D. HairMax LaserComb laser phototherapy device in the treatment of male androgenetic alopecia: A randomized, double-blind, sham device- controlled, multicentre trial. Clinical Drug Investigation. 2009;29(5):283-92
  122. Satino JL, Markou M. Hair regrowth and increased hair tensile strength using the HairMax LaserComb for low-level laser therapy. International Journal of Cosmetic Surgery and Aesthetic Dermatology. 2003;5(2):113-7
  123. Lanzafame RJ, Blanche RR, Bodian AB, Chiacchierini RP, Fernandez- Obregon A, Kazmirek ER. The growth of human scalp hair mediated by visible red light laser and LED sources in males. Lasers in Surgery and Medicine. 2013;45(8):487-95
  124. Perper M, Aldahan AS, Fayne RA, et al. Efficacy of fractional lasers in treating alopecia: a literature review. Lasers Med Sci. 2017;32:1919–1925
  125. Meephansan J, Ungpraphakorn N, Ponnikorn S, et al. Efficacy of 1,550-nm erbium-glass fractional laser treatment and its effect on the expression of insulin-like growth factor 1 and Wnt/β- catenin in androgenetic alopecia. Dermatol Surg. 2018;44:1295–1303
  126. KIM WS, Lee HI, Lee JW, et al. Fractional photothermolysis laser treatment of male pattern hair loss. Dermatol Surg. 2011;37:41–51. 84
  127. Suchonwanit P. Rojhirunsakool S and Khunkhet S. A randomized, investigator-blinded, controlled, split-scalp study of the efficacy and safety of a 1550-nm fractional erbium-glass laser, used in combination with topical 5% minoxidil versus 5% minoxidil alone, for the treatment of androgenetic alopecia. Lasers Med Sci. 2019;34:1856–1864
  128. Cruciani M, Masiello F, Pati I, Marano G, Pupella S, De Angelis V. Platelet-rich plasma for the treatment of alopecia: a systematic review and meta-analysis. Blood Transfus. 2021 Nov 15. doi: 10.2450/2021.0216-21. Epub ahead of print. PMID: 34967722
  129. Mao G, Zhang G, Fan W. Platelet-Rich Plasma for Treating Androgenic Alopecia: A Systematic Review. Aesthetic Plast Surg. 2019 Oct;43(5):1326-1336. doi: 10.1007/s00266-019- 01391-9. Epub 2019 Jun 11. PMID: 31187167
  130. Giordano S, Romeo M, Lankinen P. Platelet-rich plasma for androgenetic alopecia: Does it work? Evidence from meta analysis. J Cosmet Dermatol. 2017 Sep;16(3):374-381. doi: 10.1111/jocd.12331. Epub 2017 Mar 13. PMID: 28296142
  131. Schiavone G, Raskovic D, Greco J, Abeni D. Platelet-rich plasma for androgenetic alopecia: a pilot study. Dermatologic Surgery. 2014;40(9):1010-9
  132. Gkini MA, Kouskoukis AE, Tripsianis G, Rigopoulos D, Kouskoukis K. Study of platelet- rich plasma injections in the treatment of androgenetic alopecia through an one-year period. Journal of cutaneous and aesthetic surgery. 2014;7(4):213-9
  133. Starace M, Alessandrini A, Brandi N, Piraccini BM. Prelimi- nary results of the use of scalp microneedling in different types of alopecia. J Cosmet Dermatol. 2019. https://doi.org/10.1111/ jocd.13061
  134. Dhurat R, Sukesh M, Avhad G, Dandale A, Pal A, Pund P. A randomized evaluator blinded study of effect of microneedling in androgenetic alopecia: a pilot study. Int J Trichol. 2013;5(1):6– 11
  135. Fertig RM, Gamret AC, Cervantes J, Tosti A. Microneedling for the treatment of hair loss? J Eur Acad Dermatol Venereol. 2018;32(4):564–9
  136. Lengg N., Heidecker B., Seifert B., Trüeb R. Treatment of Telogen Hair Loss in Apparently Healthy Women with Pantogar. Therapy. 2007; 4:59-65
  137. Budde J., Tronnier H., Rahlfs V.W., Frei-Kleiner S. Systemische Therapie von diffusem Effluvium und Haarstrukturschaden. Hautarzt 1; 44: 380-384, 1993
  138. Unger W, Shapiro R. Commentary on Russell Knudsen's effect of medical therapy on surgical planning. In: UngerWP, Shapiro R, eds. Hair Transplantation. 4th ed. New York, NY: Marcel Dekker; 2004:148-151
  139. Leavitt M, Perez-Meza D, Rao NA et al. Effects of finasteride (1 mg) on hair transplant. Dermatol Surg 2005; 31: 1268– 1276
  140. Bouhanna P. Topical minoxidil used before and after hair transplantation surgery // J. Dermatol. Sur. Oncol. 1989. Vol. 15. P. 50-53
  141. Bouhana P. Androgenetic alopecia: combining medical and surgical treatments // Dermatol.Surg. 2003. Vol. 29. P.1130-1134
  142. Greco J., Brandt R. The effects of autologous platelet rich plasma and various growth factors on non-transplanted miniaturized hair. // Hair Transplant. Forum Int. 2009. Vol. 19, N 2. P. 49-504
  143. Bouhana P. Amgar G. Platelet-rich plasma: a therapy for hair growth // Prime. 2013. Vol.3, N 4. P. 20-31
  144. Uebel CO, da-Silva JB, Cantarelli D et al. The role of platelet plasma growth factors in male pattern baldness surgery. Plast Reconstr Surg 2006; 118: 1458– 1466
  145. Brockschmidt FF, Heilmann S, Ellis JA, Eigelshoven S,et all. Susceptibility variants on chromosome 7p21.1 suggest HDAC9 as a new candidate gene for male-pattern baldness.Br J Dermatol. 2011 Dec;165(6):1293-302
  146. Redler A.G., Messenger R., Betz C. Genetics and other factors in the aetiology of female pattern hair loss. Exp.Dermatol. 2017 Jun;26(6):510-517

Для продолжения работы требуется Registration
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Table of contents

Данный блок поддерживает скрол*